BOARD OF DIRECTORS
Michael Hunkapiller, Ph.D.Chairman, CEO & President
Michael Hunkapiller became President & CEO of Pacific Biosciences in 2012. He is Chairman of PacBio’s Board of Directors, and has served on the Board since 2005. Dr. Hunkapiller spent over 30 years of his career helping build Applied Biosystems (“ABI,” now part of Thermo Fisher Scientific Inc.) into a market leader in the life sciences industry. From 1995 to 2004, he served as ABI’s President and General Manager. In 2004, he joined Alloy Ventures as a General Partner, and in 2005 led Alloy’s investment in PacBio.
During his term at ABI, Dr. Hunkapiller developed the R&D strategies and alliances that elevated ABI to be the foremost supplier of molecular-biology reagents and instrumentation in academic and industrial laboratories. He was also a founder of ABI’s sister company, Celera Genomics, and Senior Vice President of Applera Corporation (Celera’s parent company).
Prior to joining ABI, Dr. Hunkapiller was a senior research fellow in the Division of Biology at the California Institute of Technology. He received a B.S. in Chemistry from Oklahoma Baptist University and a Ph.D. in Chemical Biology from the Division of Chemistry and Chemical Engineering at Caltech. He has authored more than 100 scientific publications, is an inventor on more than two-dozen patents, and has served on the editorial boards of several scientific journals. He has received several awards for his contributions to life science research.Chairman of the Board
David BotsteinChief Scientific Officer, Calico Life Sciences, LLC
David Botstein, Ph.D., is Chief Scientific Officer of Calico Life Sciences, LLC. He was the Anthony B. Evnin Professor of Genomics, Emeritus at Princeton University, where he also served as Director of the Lewis-Sigler Institute for Integrative. From 1990-2003 he was Chairman of the Department of Genetics at Stanford University. From 1987-1990 he was Vice President for Science at Genentech and remained a member of its Science Resource Board until 2014. He is a member of the National Academy of Sciences and the Institute of Medicine, and has received numerous awards for his achievements in science. Dr. Botstein has made fundamental contributions to modern genetics, including the discovery of many yeast and bacterial genes and the establishment of key techniques that are commonly used today. In 1980, Botstein and three colleagues proposed a method for mapping genes that laid the groundwork for the Human Genome Project. Dr. Botstein holds a Ph.D. in Human Genetics from the University of Michigan and an A.B. in Biochemical Sciences from Harvard.Independent Director
Bill EricsonFounding Partner, Wildcat Venture Partners
William Ericson has been a member of our Board of Directors since 2004 and our Lead Independent Director since 2010. Mr. Ericson is a Founding Partner at Wildcat Venture Partners where he focuses on investments in Digital Health. He is also a General Partner at Mohr Davidow Ventures (MDV) where he has led the firm’s focus on personalized medicine investing since 2003.
Mr. Ericson holds a B.S.F.S. from Georgetown University School of Foreign Service and a J.D. from Northwestern University School of Law. We believe that Mr. Ericson possesses specific attributes that qualify him to serve as a member of our Board of Directors, including his experience with multiple companies in the life sciences industry and his focus on companies with molecular diagnostic platforms that will enable the vision of personalized medicine.Independent Director
Christian Henry is a diverse executive with more than 20 years of experience in growing companies in the life sciences industry. From 2005 through January 2017, Mr. Henry was a key member of the executive team at Illumina, Inc. (NASDAQ: ILMN) where he served in a number of different roles including Chief Financial Officer, Chief Commercial Officer and General Manager of the Life Sciences Business. During his time at Illumina he helped guide the company to grow from less than $75 million in revenue to more the $2.2 billion. Prior to Illumina, Mr. Henry was Chief Financial Officer for Tickets.com, a publicly traded online ticket provider, which was acquired by Major League Baseball Advanced Media, LP. Mr. Henry also served as Vice President of Finance and Corporate Controller for Affymetrix, Inc., (NASDAQ: AFFX), and held a similar position at Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.). Mr. Henry earned a BA in biochemistry and cell biology from the University of California, San Diego and an MBA from the University of California, Irvine.
Randy LivingstonVice President for Business Affairs and Chief Financial Officer, Stanford University
Randy Livingston has been Vice President for Business Affairs and Chief Financial Officer of Stanford University since 2001. Before joining Stanford, Mr. Livingston served as the Executive Vice President, Chief Financial Officer and a Director of OpenTV Corp. from 1999 to 2001. Prior to joining OpenTV, Mr. Livingston served as a consultant and part-time Chief Financial Officer for Silicon Valley technology companies with such diverse specialties as Genomics, Internet Commerce, Medical Devices, Chemical Synthesis and Enterprise Software. Previously, he was director of corporate development at Apple Computer and Chief Financial Officer for Taligent, Inc., a 400-employee Apple-IBM-Hewlett-Packard joint venture system softward comany. Mr. Livingston currently serves as a director of eHealth, Inc.
Mr. Livingston holds a B.S. in Mechanical Engineering and an M.B.A. from Stanford University.Independent Director
John F. Milligan, Ph.D.President and Chief Executive Officer, Gilead Sciences
Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was named Chief Operating Officer in 2007 and President in 2008. Dr. Milligan was appointed Chief Executive Officer and elected to the Board of Directors of Gilead in 2016.
Dr. Milligan is a Trustee of Ohio Wesleyan University.
Dr. Milligan received his B.A. from Ohio Wesleyan University, his Ph.D. in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.Independent Director
Marshall L. MohrSenior Vice President & Chief Financial Officer, Intuitive Surgical Inc.
Since March 2006, Marshall L. Mohr has been the Senior Vice President and Chief Financial Officer of Intuitive Surgical, Inc., a provider of surgical robotics. Prior to joining Intuitive Surgical, Mr. Mohr served as Vice President and Chief Financial Officer of Adaptec, Inc. Before 2003, Mr. Mohr was an Audit Partner with PricewaterhouseCoopers LLP where he was most recently the Managing Partner of the firm's West Region Technology Industry Group and led its Silicon Valley accounting and auditing advisory practice. Since 2005, Mr. Mohr has been a member of the Board of Directors and Chairman of the Audit Committee of Plantronics, Inc., a provider of lightweight communications headsets and telephone headset systems, and also served as a member of the Board of Directors and Chairman of the Audit Committee of Atheros Communications, Inc., a developer of semiconductor system solutions for wireless communications products, from November 2003 to May 2011 when Atheros was sold to Qualcomm, Inc.
Mr. Mohr holds a Bachelor of Business Administration in Accounting and Finance from Western Michigan University.Independent Director
Kathy Ordoñez brings more than 30 years of experience in the life sciences and diagnostics industries. From January 2012 until June 2013, Ms. Ordoñez was a Senior Vice President at Quest Diagnostics Inc., a leading provider of diagnostic information services, where she was initially responsible for leading the company’s R&D effort and later provided oversight to multiple businesses commercializing diagnostic products and testing services. She joined Quest Diagnostics as part of its acquisition of Celera Corporation, a leading provider of genetic testing products for HIV resistance, Cystic Fibrosis and high complexity tissue transplantation, in 2011. From April 2002 until May 2011, Ms. Ordoñez was the Chief Executive Officer at Celera and she founded Celera Diagnostics in December 2000. From 1985 until 2000, Ms. Ordoñez held several senior positions at Hoffmann- La Roche, overseeing the formation of Roche Molecular Systems, where she served as President and Chief Executive Officer, and led the wide-scale commercial application of the Polymerase Chain Reaction (PCR) technology to the research, diagnostic and forensic fields. Ms. Ordoñez also served as Director, non-Executive Chairman, and Chief Executive Officer of RainDance Technologies, Inc., which was sold to Bio-Rad Laboratories, Inc. in February 2017.
Lucy ShapiroDevelopmental Biology Professor, Stanford University School of Medicine
Dr. Shapiro currently serves as the Virginia and D.K. Ludwig Professor of Cancer Research and the Director of the Beckman Center for Molecular and Genetic Medicine at Stanford University's School of Medicine, where she has been as a faculty member since 1989. Dr. Shapiro is a co-founder and director of Anacor Pharmaceuticals, Inc., which was acquired by Pfizer in 2016. In 2016, she founded a second anti-infectives company, Boragen, LLC. In 1989, Dr. Shapiro founded Stanford University's Department of Developmental Biology, and served as its Chairman from 1989 to 1997. Prior to that, Dr. Shapiro served as Chair of the Department of Microbiology and Immunology in the College of Physicians and Surgeons of Columbia University. She received a B.A. from Brooklyn College and a Ph.D. in Molecular Biology from the Albert Einstein College of Medicine.
Dr. Shapiro has received numerous awards including the National Medal of Science. She has been and elected to the National Academy of Sciences, the American Academy of Microbiology, the American Academy of Arts and Sciences and the National Academy of Medicine for her work in the fields of molecular biology and microbiology. Dr. Shapiro previously served as a non-executive director of GlaxoSmithKline plc from 2001 to 2006. Dr. Shapiro was also a Director of Gen-Probe, Inc. from 2008 to 2012.Independent Director